RedHill Biopharma Ltd. (RDHL) stock
RDHLNasdaqPharmaceutical Preparations
$0.38−0.01 (-1.60%)
Close on Nov 13, 2026Market cap $1.91MP/E –Yield –
RedHill Biopharma EPS
Diluted earnings per share is net income divided by the share count including options and convertible securities.
For fiscal 2025 it was $0.00. The highest annual figure on record is $0.17 in fiscal 2018.
Annual eps
| Period | Period end | Value | Change |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | $0.00 | – |
| FY2024 | Dec 31, 2024 | $0.00 | -100.0% |
| FY2023 | Dec 31, 2023 | $0.01 | – |
| FY2022 | Dec 31, 2022 | -$0.12 | – |
| FY2021 | Dec 31, 2021 | -$0.21 | – |
| FY2020 | Dec 31, 2020 | -$0.21 | – |
| FY2019 | Dec 31, 2019 | -$0.14 | -182.4% |
| FY2018 | Dec 31, 2018 | $0.17 | – |
| FY2017 | Dec 31, 2017 | -$0.26 | – |
| FY2016 | Dec 31, 2016 | -$0.24 | – |
| FY2015 | Dec 31, 2015 | -$0.19 | – |
Quarterly eps
Change is against the same quarter a year earlier.
| Period | Period end | Value | Change |
|---|---|---|---|
| Q2 FY2022 | Jun 30, 2022 | -$0.02 | -140.0% |
| Q2 FY2021 | Jun 30, 2021 | -$0.06 | -200.0% |
| Q2 FY2020 | Jun 30, 2020 | $0.04 | – |
| Q2 FY2019 | Jun 30, 2019 | $0.04 | – |
| Q2 FY2018 | Jun 30, 2018 | $0.05 | – |
| Q2 FY2017 | Jun 30, 2017 | $0.06 | – |
- Revenue
- Gross Profit
- Operating Income
- Net Income
- EBITDA
- Free Cash Flow
- Operating Cash Flow
- R&D Expenses
- Gross Margin
- Operating Margin
- Profit Margin
- Total Debt
- Cash
- Total Assets
- Shares Outstanding
- Market Cap
- Enterprise Value
- PE Ratio
- Price to Sales Ratio
- Price to Book Ratio
- EV/EBITDA
- Price to Free Cash Flow
- All statistics
See a number that looks wrong?